Biomarkers in Patients With Advanced Rhabdomyosarcoma



Status:Completed
Conditions:Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:5/19/2016
Start Date:August 2012

Use our guide to learn which trials are right for you!

Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas

This research trial studies tumor tissue to identify important proteins and biomarkers from
patients with rhabdomyosarcoma that has spread to other places in the body and usually
cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients
with cancer in the laboratory may help doctors identify biomarkers related to cancer.

PRIMARY OBJECTIVES:

I. To investigate whether the expression of a subset of proteins (by immunohistochemistry),
known to be Involved in the paired box (Pax)3, Pax7, and Patched-1 neuromuscular development
pathways, are dysregulated in advanced and relapsed alveolar and embryonal
rhabdomyosarcomas.

OUTLINE:

Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in
each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray
analysis.

Inclusion Criteria:

- 8 tissue microarrays (TMA) slides of the following diseases available:

- Alveolar rhabdomyosarcoma

- Embryonal rhabdomyosarcoma

- Anaplastic rhabdomyosarcoma
We found this trial at
1
site
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials